Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/31482332http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/31482332http://www.w3.org/2000/01/rdf-schema#comment"

Purpose

The clinical significance of cytokeratin fraction 21-1 (CYFRA 21-1) for patients with head and neck cutaneous squamous cell carcinoma (CSCC) is unknown. Thus, the aim of the study was to evaluate the clinical value of CYFRA 21-1 in the context of treatment and follow-up for these patients.

Methods

The clinical, histological and laboratory data of a total of 55 patients with the first diagnosis of head and neck cutaneous squamous cell carcinoma (T1-T4, N0-N2b, M0-1) between 2003 and 2017 were retrospectively analyzed. In 25 cases, the primary tumor could be treated successfully without residual or recurrent disease in the further course. The average follow-up period was 2.3 years. In all patients, pretherapeutic determination of CYFRA 21-1 was performed using the ECLIA test kit. The cut-off value was set at 3.3 ng/ml.

Results

In 18 patients (32.7%), regional recurrence was found in the course of treatment. Distant metastases could be observed in two patients (3.6%). In these cases, no significant increase of CYFRA 21-1 blood concentration was detected at the time of recurrence/metastasis. At the time of the first diagnosis, the mean value of CYFRA 21-1 blood concentration was 2.4 ng/ml; and in cases of regional recurrence or distant metastases, the initial mean CYFRA 21-1 concentration was 2.0 ng/ml. There was no statistically significant relationship between CYFRA 21-1 blood concentration and analyzed tumor characteristics.

Conclusions

According to current knowledge, the tumor marker CYFRA 21-1 is not clinically significant for treatment and follow-up of patients with head and neck CSCC."xsd:string
http://purl.uniprot.org/citations/31482332http://purl.org/dc/terms/identifier"doi:10.1007/s00405-019-05614-2"xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/author"Hoch M."xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/author"Birk R."xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/author"Hoch S."xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/author"Schultz J.D."xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/author"Stuck B.A."xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/author"Gehrt F."xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/author"Pavel F.L."xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/author"Rudhart S.A."xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/date"2019"xsd:gYear
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/name"Eur Arch Otorhinolaryngol"xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/pages"3467-3475"xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/title"CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma?"xsd:string
http://purl.uniprot.org/citations/31482332http://purl.uniprot.org/core/volume"276"xsd:string
http://purl.uniprot.org/citations/31482332http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/31482332
http://purl.uniprot.org/citations/31482332http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/31482332
http://purl.uniprot.org/uniprot/#_P08727-mappedCitation-31482332http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/31482332
http://purl.uniprot.org/uniprot/P08727http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/31482332